This CPB has been revised to: (i) designate Elelyso (taliglucerase alfa), Vpriv (velaglucerase alfa), Zavesca (miglustat) as more costly medically necessary brands of enzyme replacement therapy for Gaucher Disease; (ii) designate Cerezyme (imiglucerase) as a least cost medically necessary brand of enzyme replacement therapy for Gaucher Disease.